Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02939287 · OUTCOME

Acute Complete Response

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan · Source last updated 2024-10-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
0 (transplant time) to 24 hours post-transplant

What was measured

no emesis or rescue therapy; Acute complete response defined as no emesis or rescue therapy required from time point of 0 to 24 hours following melphalan therapy administration

Analysis population: No data were collected or analyzed for this outcome.

Groups in this outcome

Aprepitant

aprepitant plus standard anti-emetic regimen o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1: Add aprepitant to anti-emetic regimen

Olanzapine

olanzapine plus standard anti-emetic regimen Olanzapine10 mg orally daily on Days -1,0,+1 and +2: add olanzapine to anti-emetic regimen

Aprepitant Plus Olanzapine

aprepitant and olanzapine plus standard anti-emetic regimen Aprepitant plus Olanzapine: add aprepitant and olanzapine to anti-emetic regimen

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Aprepitant0
Olanzapine0
Aprepitant Plus Olanzapine0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    units
    Participants
description
no emesis or rescue therapy; Acute complete response defined as no emesis or rescue therapy required from time point of 0 to 24 hours following melphalan therapy administration
groups
  1. description
    aprepitant plus standard anti-emetic regimen o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1: Add aprepitant to anti-emetic regimen
    id
    OG000
    title
    Aprepitant
  2. description
    olanzapine plus standard anti-emetic regimen Olanzapine10 mg orally daily on Days -1,0,+1 and +2: add olanzapine to anti-emetic regimen
    id
    OG001
    title
    Olanzapine
  3. description
    aprepitant and olanzapine plus standard anti-emetic regimen Aprepitant plus Olanzapine: add aprepitant and olanzapine to anti-emetic regimen
    id
    OG002
    title
    Aprepitant Plus Olanzapine
population Description
No data were collected or analyzed for this outcome.
reporting Status
POSTED
time Frame
0 (transplant time) to 24 hours post-transplant
title
Acute Complete Response
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice